Abstract
This letter is in response to the questions raised by Kawasaki et al. regarding our recently published paper on INSM1 as a novel prognostic neuroendocrine (NE) marker in breast cancer.1 We appreciate their comments on our study and thank them for sharing their experience.2 One question that they raised was about the proportion and morphology of breast cancers showing INSM1+/chromogranin (CG)–/synaptophysin (SYN)–. The other point was on the morphological findings of invasive cancers showing CD56 reactivity exclusively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
